Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DSP: Overseas Subsidiaries Boost Sales
May 24, 2010
- New Indication for Actemra Approved in Europe
May 24, 2010
- Shionogi: Crestor, US Subsidiary Drive Sales Up 22.4%
May 24, 2010
- Korosho Calls For Cautions for ILD in Patients Receiving Statins
May 24, 2010
- Otsuka HD: Sales of Healthcare Business Up 5.6%
May 24, 2010
- GAMMAGARD Improves Cognitive Function in AD Patients in PII: Baxter
May 24, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (1)
May 24, 2010
- Gaslon Accelerates Gastric Ulcer Healing after HP Infection
May 24, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (2)
May 24, 2010
- Humira Achieves Clinical Remission Rate of 17.7% in 24 Weeks: PMS Data
May 24, 2010
- Janssen, Takeda to Copromote VELCADE in Japan
May 24, 2010
- Equa Can Become 1st-Choice DPP-4 Inhibitor: Prof. Kadowaki
May 24, 2010
- Santen Launches Tafluprost in South Korea
May 24, 2010
- Proper Use of Topical Steroids Should Be Promoted: Prof. Horio
May 24, 2010
- Daiichi Sankyo Voluntarily Recalls Amplit Tablets 25 mg
May 24, 2010
- Erbitux Makes Hepatic Metastasis of Colon Cancer Curable: Prof. Sugihara
May 24, 2010
- Need for Biosimilars Highlighted at CPhI 2010 Panel Discussion
May 24, 2010
- Cervarix Shows Immunological Responses Significantly Higher Than Gardasil: Dr Einstein
May 24, 2010
- Joji Nakayama to Be Appointed President of Daiichi Sankyo
May 24, 2010
- Teva-Kowa to Integrate Taisho Pharm's Marketing Division in July
May 24, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…